Addition of Losartan to Immune Checkpoint Blockade Improves Tumor Control and Neurological Outcomes in Models of NF2-Related Schwannomatosis
Cellular and Molecular Bioengineering · 15.07.2026
DOI: 10.1007/s12195-026-00929-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cellular and Molecular Bioengineering, online erschienen am 15.07.2026. Verfasst von Simeng Lu und 9 weiteren Autor:innen. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIH-NINDS, NIH-NIDCD, DoD.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Förderung
- NIH-NINDS
- NIH-NIDCD
- DoD
- American Cancer Society
Zitieren
APA
Lu, S., Chen, J., Wu, L., Sun, Y., Yin, Z., Hernandez-Meadows, M., Jones, A. P., Stemmer-Rachamimov, A., Plotkin, S. R., & Xu, L. (2026). Addition of Losartan to Immune Checkpoint Blockade Improves Tumor Control and Neurological Outcomes in Models of NF2-Related Schwannomatosis. Cellular and Molecular Bioengineering. https://doi.org/10.1007/s12195-026-00929-7
Vancouver
Lu S, Chen J, Wu L, Sun Y, Yin Z, Hernandez-Meadows M, et al. Addition of Losartan to Immune Checkpoint Blockade Improves Tumor Control and Neurological Outcomes in Models of NF2-Related Schwannomatosis. Cellular and Molecular Bioengineering. 2026. doi:10.1007/s12195-026-00929-7
BibTeX
@article{Lu2026,
author = {Lu, Simeng and Chen, Jie and Wu, Limeng and Sun, Yao and Yin, Zhenzhen and Hernandez-Meadows, Miriam and Jones, Adam P. and Stemmer-Rachamimov, Anat and Plotkin, Scott R. and Xu, Lei},
title = {Addition of Losartan to Immune Checkpoint Blockade Improves Tumor Control and Neurological Outcomes in Models of NF2-Related Schwannomatosis},
journal = {Cellular and Molecular Bioengineering},
year = {2026},
doi = {10.1007/s12195-026-00929-7}
}
EUVIMED